Therapeutic Application of NavacimTM, a Precision Nanomedicine Platform, in IBD
Time: 1:30 pm
day: Day One
Details:
- History of type-1 regulatory T cells and navacim in ameliorating inflammatory diseases
- Nonclinical safety and pharmacology studies supporting the use of navacims in first-in-human studies
- Clinical translational and proof-of-concept studies
